Reasons to use herbal supplements with sabal palm fruit extract (Serenoa repens) in patients with benign prostatic hyperplasia from urologist’s perspective Review article
Article Sidebar
Published:
Jun 30, 2016
Keywords:
BPH, Serenoa repens, ethanol extract, modes of action, efficacy, safety
Main Article Content
Abstract
Benign prostatic hyperplasia (BPH) is one of the most common conditions in men aged 50 and older. Use of herbal supplements is an alternative to drug therapy. The article presents an overview of literature discussing efficacy of the ethanol extract of sabal palm fruit (Serenoa repens) in patients with BPH.
Article Details
How to Cite
Jarema , R. K. (2016). Reasons to use herbal supplements with sabal palm fruit extract (Serenoa repens) in patients with benign prostatic hyperplasia from urologist’s perspective. Medycyna Faktow (J EBM), 9(2(31), 126-128. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2249
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995; 22: 247-261.
2. Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
3. Isaacs JT, Coffey DS. Etiology and disease processes of benign prostatic hyperplasia. Prostate 1989; 2(suppl 2): 33-40.
4. Launoit Y, Kiss R, Jossa V et al. The influence of dihydrotestosterone, testosterone, estradiol, progesterone or prolactin on the cell kinetics of human hyperplastic tissue in organ culture. Prostate 1988; 13: 143-153.
5. Schalken JA. The androgen cascade in ageing men: blessing or curse? Eur Urol 2003; suppl 2; 2(8): 8-12.
6. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5-α-reductase types I and II inhibitor – new evidence in a coculture model of BPH. Prostate 1999; 40(4): 232-241.
7. Wilt TJ, Ishani A, Rutks I, MacDonald R: Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 2000; 3(4A): 459-472.
8. Wilt TJ, Ishani A, Stark G et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280(18): 1604-1609.
9. Sultan C, Terraza A, Devillier C et al. Inhibition of androgen metabolism and binding by a liposterolic extract of ‘Serenoa repens B’ in human foreskin fibroblasts. J Steroid Biochem 1984; 20: 515-519.
10. Bayne CW, Ross M, Donelly F, Habib FK. The selectivity and specificity of the actions of the lipidosterolic extract of Serenoa repens (Permixon®) on the prostate. J Urol 2000; 164(3 Pt 1): 876-881.
11. Breu W, Hagenlocher M, Redi K et al. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung 1992; 42(4): 547-551.
12. Tarayre JP, Delhon A, Lauressergues H et al. Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr. Ann Pharm Fr 1983; 41(6): 559-570.
13. Desgrandchamps F, Teillac P. The role of growth factors in the pathogenesis of benign prostatic hyperplasia. Biomed Pharmacother 1994; 48(suppl 1): 19-23.
14. Vacherot F, Azzouz M, Gil-Diez-De-Medina S et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. Prostate 2000; 45(3): 259-266.
15. Lawson RK. Benign prostatic hyperplasia and growth factors. Urologue A 1990; 29(1): 5-7.
16. Di Silverio F, Monti S, Sciarra A et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998; 37(2): 77-83.
17. Van Coppenolle F, Le Bourhis X, Carpentier F et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000; 43(1): 49-58.
18. Vacher P, Prevarsakaya N, Skryma R et al. The Lipidosterolic Extract from Serenoa repens Interferes with Prolactin Receptor Signal Transduction. J Biomed Sci 1995; 2(4): 357-365.
19. Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia. A multicenter open study. Curr Ther Res Clin Exper 1994; 55: 776-785.
2. Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
3. Isaacs JT, Coffey DS. Etiology and disease processes of benign prostatic hyperplasia. Prostate 1989; 2(suppl 2): 33-40.
4. Launoit Y, Kiss R, Jossa V et al. The influence of dihydrotestosterone, testosterone, estradiol, progesterone or prolactin on the cell kinetics of human hyperplastic tissue in organ culture. Prostate 1988; 13: 143-153.
5. Schalken JA. The androgen cascade in ageing men: blessing or curse? Eur Urol 2003; suppl 2; 2(8): 8-12.
6. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5-α-reductase types I and II inhibitor – new evidence in a coculture model of BPH. Prostate 1999; 40(4): 232-241.
7. Wilt TJ, Ishani A, Rutks I, MacDonald R: Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 2000; 3(4A): 459-472.
8. Wilt TJ, Ishani A, Stark G et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280(18): 1604-1609.
9. Sultan C, Terraza A, Devillier C et al. Inhibition of androgen metabolism and binding by a liposterolic extract of ‘Serenoa repens B’ in human foreskin fibroblasts. J Steroid Biochem 1984; 20: 515-519.
10. Bayne CW, Ross M, Donelly F, Habib FK. The selectivity and specificity of the actions of the lipidosterolic extract of Serenoa repens (Permixon®) on the prostate. J Urol 2000; 164(3 Pt 1): 876-881.
11. Breu W, Hagenlocher M, Redi K et al. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung 1992; 42(4): 547-551.
12. Tarayre JP, Delhon A, Lauressergues H et al. Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr. Ann Pharm Fr 1983; 41(6): 559-570.
13. Desgrandchamps F, Teillac P. The role of growth factors in the pathogenesis of benign prostatic hyperplasia. Biomed Pharmacother 1994; 48(suppl 1): 19-23.
14. Vacherot F, Azzouz M, Gil-Diez-De-Medina S et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. Prostate 2000; 45(3): 259-266.
15. Lawson RK. Benign prostatic hyperplasia and growth factors. Urologue A 1990; 29(1): 5-7.
16. Di Silverio F, Monti S, Sciarra A et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998; 37(2): 77-83.
17. Van Coppenolle F, Le Bourhis X, Carpentier F et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000; 43(1): 49-58.
18. Vacher P, Prevarsakaya N, Skryma R et al. The Lipidosterolic Extract from Serenoa repens Interferes with Prolactin Receptor Signal Transduction. J Biomed Sci 1995; 2(4): 357-365.
19. Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia. A multicenter open study. Curr Ther Res Clin Exper 1994; 55: 776-785.